Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States.  Marotta PL, Stringer KL, Mandavia AD, Davis A, Beletsky L, Hunt T, Goddard-Eckrich D, Wu E, Gilbert L, El-Bassel N.  J Ad…

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder.  Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brou…

The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases.  Stöver, H., Tarján, A., Horváth, G. et al. Harm Reduct J 18, 67 (2021). doi.org/10.1186/s12954-021-005…

EMCDDA. Prison and drugs in Europe: current and future challenges Summary This publication provides an overview of current knowledge and the latest developments in the field of drug use and prison in Europe. The report explores in depth the epidem…

New EMCDDA report underlines need to scale up drug services in prisons Current insights and future challenges on drugs and prison in Europe are explored today in a major new study published by the EU drugs agency (EMCDDA)(1). Released on the eve of…

Bayern. Interview: „Letztlich empfahl der Anstaltsarzt meinem Bruder, sich im Hof Drogen zu besorgen“ Claudia Jaworski hat ihrem heroinabhängigen Bruder Substitutionsmittel ins Gefängnis gebracht, weil ihm in Haft die Behandlung verweigert wurde –…